HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes From the HER1/EGFR Inhibitor Rash Management Forum

Oncologist - United States
doi 10.1634/theoncologist.10-5-345
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Management of EGFR-inhibitor Associated Rash: A Retrospective Study in 49 Patients

European Journal of Medical Research
Medicine
2012English

Management of Skin Rash During Egfr-Targeted Monoclonal Antibody Treatment for Gastro Intestinal Malignancies: Canadian Recommendations

Current Oncology
Oncology
2009English

Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash: A Consecutive Patient Series That Illustrates the Need for Rigorous Palliative Trials

Journal of Palliative Medicine
MedicineAnesthesiologyPain MedicineNursing
2011English

Epidermal Growth Factor Receptor (EGFR); EGFR1 (HER1; ERBB1); EPH Receptor A2 (EPHA2)

Science-Business eXchange
2011English

Lapatinib, a TKI Dual Inhibitor of Her1 and Her2 Receptors: Review of the Literature

Journal of Cancer Therapy
2012English

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue

PLoS ONE
Multidisciplinary
2013English

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

PLoS Medicine
BiochemistryBiotechnologyMolecular BiologyCell BiologyMedicine
2005English

Mouse Model of Skin Rash Syndrome Caused by Anti–epidermal Growth Factor Receptor (EGFR) Therapy

Science-Business eXchange
2013English

Minocycline Improves the Efficacy of EGFR Inhibitor Therapy: A Hypothesis

Frontiers in Oncology
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy